

**DERBYSHIRE HEALTH AND WELLBEING BOARD****03 October 2019****Report of the Director of Public Health****Update to the process for changes to the pharmaceutical list in the Health and Wellbeing area****1. Purpose of the report:**

To enable the HWB to come to a considered representation on pharmaceutical applications to NHS England within the required timeframes.

**2. Information and Analysis:****Background**

The NHS (Pharmaceutical Services, Charges and Prescribing Amendment) Regulations 2016 requires the Health and Wellbeing Board (HWB) to make representations on applications to NHS England for changes to the pharmaceutical list. The HWB representations must be submitted to NHS England within 45 days of the date of the letter received. NHS England consider all representations that are received before deciding on whether the application is granted.

Applications to NHS England can include:

- Consolidations; community pharmacies on two or more sites propose to consolidate to a single site.
- Relocations; proposals to move premises
- Additions; proposals for new pharmaceutical services

In addition to any other matter about which the HWB wishes to make representations, in the case of consolidations and relocations the response must indicate whether in the opinion of the HWB the proposal would or would not create a gap in pharmaceutical services if the application were granted.

**Current Process**

As a response to an application within the requirement timescales is unlikely to be achieved within the routine schedule of HWB meetings the following process was agreed.

1. Notification letter received from NHSE requesting HWB representation (45 days to respond)

2. Population Knowledge and Intelligence Team (KIT) undertake analysis of key considerations
3. Draft recommendation sent to Director of Public Health for review and decision
4. Director of Public Health has delegated responsibility from the HWB to sign off representation
5. Subsequent NHS England decision recorded in the quarterly Pharmaceutical Needs Assessment (PNA) supplementary statement (accessed here: <https://observatory.derbyshire.gov.uk/pna/>) and noted in the HWB round up report

### **Update to Current Process**

Following review, the following changes are proposed to incorporate a notification to HWB members via email that an application has been received and invite comments on the analysis and recommendation.

1. Notification letter received from NHSE requesting HWB representation
2. KIT undertake analysis of key considerations and complete template (see Appendix 1)
3. Analysis and draft recommendation circulated to HWB members (*aiming to allow 20 days for consideration*)
4. Following review of any feedback received the Director of Public Health is given delegated authority to sign off the HWB representation
5. Subsequent NHS England decision recorded in the quarterly Pharmaceutical Needs Assessment (PNA) supplementary statement and noted in the HWB round up report

If any application is considered particularly contentious or any notable risks are identified, a meeting to consider the key issues and any comments received on the proposal will be arranged. The meeting will consist of: the HWB Chair, Vice Chair and Director of Public Health and other officers/ members as appropriate. This group shall agree the response to be made to NHS England.

### **3. Links to the Health and Wellbeing Strategy**

The PNA is a statutory responsibility of the Health and Wellbeing Board, which has been delegated to the Director of Public Health

### **RECOMMENDATION**

The Health & Wellbeing Board is asked to approve the proposed update to the process for HWB representations on changes to the pharmaceutical list

Dean Wallace  
Director of Public Health  
Derbyshire County Council



## Section 2 – Analysis of key considerations

Key considerations
<b>Pharmaceutical Needs Assessment Statement of Provision 2018-2021 (District)</b>
<b>Change in pharmacies/ 100,000 population</b>
<b>Changes to the current service provision</b>
<i>Note: Only access to NHS commissioned service is considered under regulations. Local authority public health services and CCG are not a consideration.</i>
<b>Opening hours:</b>
<i>To consider: is existing availability sufficient? An addition may improve availability of services whilst a consolidation could result in a discrepancy in opening hours (Supplementary hours can be withdrawn by giving 3 months' notice, without any restriction)</i>
<b>Access:</b>
<i>To consider: Percentage of the local population within 'accessible distance' (one mile) of community pharmacy services? Rurality and transport links?</i>
<b>Accessibility (on-site facilities):</b>
<i>To consider: Will there be any impact on groups with protected characteristics as defined in 2010 Equality Act (i.e. age, gender, race, disability, marital status, religion, sexual orientation)?</i>
<b>Choice:</b>
<i>To consider: Will there be sufficient choice of operating providers in the locality?</i>
<b>Service Provision:</b>
<i>To consider: Will there be changes to provision of advanced and enhanced services, specialist services or equipment?</i>
<b>Are there any future proposals e.g. housing developments that could be impacted by the proposed changes?</b>